Dr Hecht on Barriers to Enrollment into the BASECAMP-1 Study in Solid Tumors
September 26th 2023J. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.
Read More
Dr Hecht on the Investigation of the Novel CAR T-Cell Therapy A2B530 in Solid Tumors
September 25th 2023J. Randolph (Randy) Hecht, MD, discusses the observational BASECAMP-1 study and the investigation of HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in the phase 1/2 EVEREST-1 study, which will investigate A2B530 in patients with solid tumors.
Read More
Dr Hecht on Barriers to CAR T-Cell Therapy Treatment in Solid Tumors
September 22nd 2023J. Randolph (Randy) Hecht, MD, discusses barriers to treatment with CAR T-cell therapy in patients with solid tumors, highlighting various efforts that investigators are spearheading to address these unmet needs.
Read More